Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2+ breast cancer

In HER2+ breast cancer patients a neoadjuvant therapy with a selected taxane plus trastuzumab and pertuzumab but without carboplatin leads to similar benefits in pathological complete response and improves tolerability